Option chain shows key data for Eterna Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Eterna Therapeutics.

Eterna Therapeutics (NASDAQ:ERNA) Stock, Option Chain

Eterna Therapeutics

Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Nvidia, Palantir, Clover Health, Joby Aviation, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATCH

ENVB

ERNA

FFIC

FRES

HAFC

HCWB

HSDT

INCY

NCNC

PRFX

QUBT

SOAR

TFFP

WAVE

ZENV

ZONE

Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket

Tesla Inc. TSLA

AEMD

APLM

AREN

CMAX

CYCN

FLYE

LAZR

LBRT

MNDR

NTLA

QMMM

SMCI

SYTA

TSLA

VVPR

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Biotech

Penny Stocks

Health Care

Market-Moving Exclusives

Exclusives

General

LCTX

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ: 

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics

Eterna Therapeutics Inc

Barclays analyst Kannan Venkateshwar maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Overweight and raises the price target from $475 to $710.

Price Target

Analyst Ratings

SPOT

Barclays Maintains Overweight on Spotify Technology, Raises Price Target to $710

WIIM

Electronic Arts shares are trading higher after the company reported better-than-expected Q3 EPS results. B of A Securities raised its price target on the stock from $130 to $132.

Benchmark analyst Cody Acree maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and lowers the price target from $200 to $170.

Benchmark Maintains Buy on Advanced Micro Devices, Lowers Price Target to $170

Private employers created 183,000 new jobs in January 2025, marking a slight acceleration from December&#8217;s upwardly revised 176,000 and beating market <a href="https://www.benzinga.com/news/econ-s">expectations of 150,000. </a>
The ADP National Employment Report, released Wednesday by Automatic Data Processing Inc., highlighted continued resilience in the private labor market ahead of Friday's highly anticipated non-farm payrolls report from the Bureau of Labor Statistics. Economists expect the government report to show a slowdown in hiring, with forecasts predicting a decline from December's 256,000 to 170,000 new jobs.
Nela Richardson, ADP&#8217;s chief economist, said: &#8220;We had a strong start to 2025 but it masked a dichotomy in the labor market. Consumer-facing industries drove hiring, while job growth was weaker in business services and production.&#8221;
<h3 class="wp-block-heading">Where Did Jobs Grow in January?</h3>
The latest data revealed a divergence in job creation, with gains concentrated in service-providing industries, while goods-producing sectors continued to lag.
Goods-producing industries shed 6,000 jobs in January, driven by a 13,000 payroll reduction in manufacturing. This marked the fourth consecutive month of job losses in the sector.
Service-providing industries, on the other hand, added 190,000 positions. Trade, transportation, and utilities led the way with 56,000 new jobs, while leisure and hospitality followed closely, adding 54,000 positions.
December&#8217;s private employment growth was also revised upward to 184,000, exceeding the consensus estimate of 150,000 tracked by TradingEconomics.
The ADP report signaled ongoing moderation in wage growth. Pay increases for job stayers in January edged up 4.7% year-over-year, while job changers saw salary gains of 6.8%, down from 7.1% in December.
These figures suggest that while the labor market remains strong, wage pressures are easing—a key factor for the Federal Reserve as it assesses the timing of potential interest rate cuts in 2025.
<h3 class="wp-block-heading">Market Reactions</h3>
The U.S. Dollar Index (DXY) – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – inched slightly higher minutes after the release, trimming losses for the day. 
Futures on major U.S. indices edged lower during premarket trading in New York. The SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was 0.4% lower by 8:25 a.m. ET. 
Shares of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) were 2.4% and 7.2% lower, respectively, weighing on tech-heavy indices. 
Gold – tracked by SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) – continued to extend record highs, with the bullion rising to $2,870 per ounce, approaching double-digit gains year-to-date. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43489453/us-stocks-likely-to-open-lower-following-alphabet-amd-earnings-walt-disney-uber-ford-qualcomm-in-focus">US Stocks Likely To Open Lower Following Alphabet, AMD Earnings: Walt Disney, Uber, Ford, Qualcomm In Focus</a></li>
</ul>
Photo: Shutterstock

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Specialty ETFs

Currency ETFs

Forex

Econ #s

Economics

Federal Reserve

ETFs

AAPL

GOOGL

PowerShares DB US Dollar Index Bullish Fund

Private Employment Rises By 183,000, Beats Estimates In January: 'Consumer-Facing Industries Drove Hiring'

Atlassian's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NYSE">TEAM</a>) short percent of float has risen 7.72% since its last report. The company recently reported that it has 4.49 million shares sold short, which is 2.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Atlassian Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738763250_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Atlassian has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Atlassian's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Atlassian's peer group average for short interest as a percentage of float is 3.02%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

TEAM

(TEAM) - Analyzing Atlassian's Short Interest

American Water Works's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) short percent of float has risen 9.62% since its last report. The company recently reported that it has 4.86 million shares sold short, which is 2.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>American Water Works Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738763245_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for American Water Works has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing American Water Works's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, American Water Works's peer group average for short interest as a percentage of float is 3.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into American Water Works's Recent Short Interest

Mobileye Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NYSE">MBLY</a>) short percent of float has risen 17.37% since its last report. The company recently reported that it has 21.44 million shares sold short, which is 29.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Mobileye Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738763240_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mobileye Global has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Mobileye Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Mobileye Global's peer group average for short interest as a percentage of float is 5.80%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MBLY

Looking Into Mobileye Global's Recent Short Interest

On Wednesday,&nbsp;Boston Scientific Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)&nbsp;reported fourth-quarter revenues of $4.56 billion, beating the&nbsp;consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of $4.424 billion</a>.
Sales increased 22.4% on a reported basis, compared to the company&#8217;s guidance range of 16.5%-18.5%, and 23.1% on an operational basis, 19.5% on an organic basis, compared to the company&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41490484/boston-scientific-q3-earnings-revenue-and-eps-beat-lifts-annual-forecast-on-strong-demand-for-heart" rel="noreferrer noopener">guidance range of 14%-16%</a>.
The company earned an adjusted EPS of 70 cents, beating the consensus of 66 cents and the management&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43489813/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2024" rel="noreferrer noopener">guidance of $0.64-$0.66</a>.
&#8220;2024 was one of the best years in the history of Boston Scientific, fueled by our innovative portfolio, the launch of our FARAPULSE Pulsed Field Ablation System, as well as significant clinical achievements and commercial excellence across businesses and regions,&#8221; said Mike Mahoney, chairman and chief executive officer of Boston Scientific.
The company&#8217;s cardiovascular segment generated sales of $2.94 billion, rising 28.8% (29.5% operationally and 27.4% organically).
<ul>
<li>Boston Scientific reported 31.1% growth in cardiology products and 21% in peripheral interventions.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/42881585/boston-scientific-expands-cardiovascular-treatment-portfolio-with-440-million-bolt-medical-deal" rel="noreferrer noopener">Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal</a>
MedSurg segment revenues increased 12.4% to $1.62 billion (13% operationally and 7% organically).
<ul>
<li>Urology led the way with a 19.5% increase. Neuromodulation (+11.4%) and Endoscopy (7%) followed.</li>
</ul>
Outlook: Boston Scientific forecasts net sales growth of approximately 12.5%-14.5% in 2025 on a reported basis and approximately 10%-12% on an organic basis.
The company estimates 2025 adjusted EPS $2.80-$2.87 compared to consensus of $2.81.
The company estimates net sales growth for the first quarter of 2025 of approximately 17%-19% on a reported basis and approximately 14%-16% on an organic basis, with adjusted EPS of $0.66-$0.68 compared to consensus of $0.64.
Price Action:&nbsp;BSX stock is up 0.84% at $104.41 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43474141/tyson-foods-stock-trading-around-fair-value-analyst-upgrades-stock-to-neutral" target="_blank" rel="noreferrer noopener">Tyson Foods Stock Trading Around Fair Value, Analyst Upgrades Stock To Neutral</a></li>
</ul>

Earnings

Large Cap

Guidance

Boston Scientific Clocks 22% Jump In Q4 Sales On Strong Heart Devices, Profit And Guidance Exceeds Expectations

Barclays analyst Adrienne Yih maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Overweight and lowers the price target from $144 to $98.

Barclays Maintains Overweight on PVH, Lowers Price Target to $98

Stanley Black & Decker Exec Says If 10% China Tariffs Remain, See Annualized, Unmitigated Hit Of About $90M-$100M

Barclays analyst Alex Scott maintains Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) with a Equal-Weight and raises the price target from $128 to $134.

Barclays Maintains Equal-Weight on Prudential Financial, Raises Price Target to $134

Barclays analyst Terry Ma maintains MGIC Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTG#NYSE">MTG</a>) with a Equal-Weight and raises the price target from $25 to $26.

Barclays Maintains Equal-Weight on MGIC Investment, Raises Price Target to $26

Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) will release its first quarter fiscal 2025 financial results, after the <a href="https://www.benzinga.com/quote/QCOM/earnings">closing bell, on Wednesday.</a>
Analysts expect the San Diego, California-based company to report quarterly earnings at $2.96 per share, up from $2.75 per share in the year-ago period. Qualcomm projects quarterly revenue of $10.9 billion, compared to $9.92 billion a year earlier, according to data from Benzinga Pro.
On Jan. 17, Barclays analyst Tom O&#8217;Malley maintained Qualcomm with an Overweight rating and lowered the price target from $200 to $185.
With the recent buzz around Qualcomm, some investors may be eyeing potential gains from the company's dividends too. As of now, Qualcomm offers an annual dividend yield of 1.96%, which is a quarterly dividend amount of 85 cents per share (3.40 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $305,416 or around 1,765 shares. For a more modest $100 per month or $1,200 per year, you would need $61,083 or around 353 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($3.40 in this case). So, $6,000 / $3.40 = 1,765 ($500 per month), and $1,200 / $3.40 = 353 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
QCOM Price Action: Shares of Qualcomm gained 1.6% to close at $173.04 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>
Photo: Shutterstock

Long Ideas

QCOM

How To Earn $500 A Month From Qualcomm Stock Ahead Of Q1 Earnings

Barclays analyst Benjamin Budish maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Overweight and lowers the price target from $185 to $181.

Barclays Maintains Overweight on KKR, Lowers Price Target to $181

Emerson Electric Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) shares are trading lower premarket on Wednesday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43490268/emerson-reports-first-quarter-2025-results-updates-2025-outlook" rel="noreferrer noopener">reported&nbsp;first-quarter FY25 results</a>.
Net sales growth of 1% year over year (Y/Y) to $4.175 billion missed the consensus of $4.23 billion.
Underlying sales were up 2% Y/Y and underlying orders increased by 1% Y/Y <a href="https://www.emerson.com/documents/corporate/emerson-reports-first-quarter-2025-results-updates-2025-outlook-en-us-11470388.pdf" target="_blank" rel="noreferrer noopener">in </a>the quarter.
Sales by Segments: Final Control&nbsp;$940 million (+4%), Measurement &amp; Analytical&nbsp;$947 million (+3%), Discrete Automation&nbsp;$613 million (-5%); Safety &amp; Productivity&nbsp;$322 million (-3%), Control Systems &amp; Software&nbsp;$675 million (+2%), AspenTech&nbsp;$257 million (+18%), and Test &amp; Measurement&nbsp;$382 million (-6%).
Adjusted Segment EBITDA was $1.169 billion compared to $1.014 billion in the prior year quarter and the margin improved to 28.0% from 24.6% a year ago quarter.
Adjusted EPS improved&nbsp;13% Y/Y to&nbsp;$1.38,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$1.28</a>.
Emerson's operating cash flow for the quarter totaled $777 million, compared to $444 million in the prior year; free cash flow was $694 million (+89% Y/Y).
Emerson held cash and equivalents of&nbsp;$2.83 billion as of December-end.
Dividend: Emerson declared a quarterly cash dividend per share of&nbsp;$0.5275, payable on March 10, to stockholders of record on&nbsp;February 14, 2025.
"We reiterate our guide for underlying sales, earnings per share and cash flow driven by resilient demand in process and hybrid markets, expected second half discrete recovery and our proven ability to execute,&#8221; Emerson president and CEO Lal Karsanbhai said.
&#8221;Our team remains energized, and we look forward to continuing the positive momentum across our business, including progressing in the final phase of our portfolio transformation.&#8221;
Outlook:&nbsp;For FY25, Emerson Electric now expects its net sales growth&nbsp;outlook of&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">1.5% &#8211; 3.5% (vs. 3.5%&nbsp;–&nbsp;5.5% prior)</a>.
The company reaffirmed the outlook for underlying sales growth of&nbsp;3%&nbsp;–&nbsp;5%&nbsp;and adjusted EPS of&nbsp;$5.85&nbsp;–&nbsp;$6.05 vs.&nbsp;consensus&nbsp;$5.94.
Emerson continues to expect an operating cash flow of&nbsp;$3.6 billion&nbsp;–&nbsp;$3.7 billion and an FCF of&nbsp;$3.2 billion&nbsp;–&nbsp;$3.3 billion for FY25.
For the&nbsp;second quarter, the company projects net sales growth of&nbsp;(0.5)% &#8211; 0.5%&nbsp;and adjusted EPS of&nbsp;$1.38 &#8211; $1.42 vs. consensus of&nbsp;$1.46.
Emerson expects to return around $3.2 billion to shareholders through around $2.0 billion of share buyback and about $1.2 billion of dividend payments for 2025.
Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/01/43229951/emerson-electric-to-buy-out-aspentech-minority-stake-in-7-2-billion-cash-deal" rel="noreferrer noopener">Emerson Electric To Buy Out AspenTech Minority Stake In $7.2 Billion Cash Deal</a>
Investors can gain exposure to the stock via&nbsp;ProShares S&amp;P Kensho Smart Factories ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAKX#NYSE">MAKX</a>) and&nbsp;Themes US Infrastructure ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWAY#NASDAQ">HWAY</a>).
Price Action: EMR shares are down 0.52% at $127.03 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/43402048/deal-dispatch-sage-and-silvus-are-up-for-sale-mrbeast-secures-20b-for-tiktok" target="_blank" rel="noreferrer noopener">Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok</a></li>
</ul>
Photo: Shutterstock

Dividends

Buybacks

HWAY

MAKX

Emerson Q1 Results: Resilient Process & Hybrid Markets Offset Weak Discrete Automation

LNTH

Lantheus Holdings Announces Piflufolastat F 18 Data Will Be Presented At The 2025 American Society Of Clinical Oncology Genitourinary Cancers Symposium, Taking Place February 13-15, 2025, In San Francisco, CA

Barclays analyst Tim Long maintains Juniper Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) with a Equal-Weight and raises the price target from $37 to $39.

JNPR

Barclays Maintains Equal-Weight on Juniper Networks, Raises Price Target to $39

ESTCP will Demonstrate Treatment Options for DoD Installations Impacted by Hazardous Chemicals Found in Firefighting Foams, Industrial Processes, and Contaminated Water Sources
U.S. National Defense Authorization Act Mandates Transition to Fluorine-Free Firefighting Foams at DoD Installations, Highlighting Growing Demand for Reliable and Scalable PFAS Destruction Technologies

SCWO

374Water To Demonstrate Commercial-Scale PFAS Destruction Capabilities In Upcoming DoD Project

Barclays analyst Saket Kalia maintains Intapp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTA#NASDAQ">INTA</a>) with a Equal-Weight and raises the price target from $63 to $68.

INTA

Barclays Maintains Equal-Weight on Intapp, Raises Price Target to $68

In the wake of a significant upswing in the cryptocurrency market, crypto exchange&nbsp;Bullish Global&nbsp;is reportedly contemplating&nbsp;an initial public offering (IPO)&nbsp;in 2025. 
What Happened: Bullish Global, a subsidiary of Block.one, is considering its first public share sale in 2025, as per a Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-02-04/peter-thiel-backed-crypto-firm-bullish-weighs-ipo">report</a> on Wednesday. The company is said to be collaborating with Jefferies Financial Group on the potential listing.
Bullish Global, led by CEO Tom Farley, has over 275 employees globally and operates in Hong Kong, the U.S., and Europe. The parent company, Block.one, is steered by Brendan Blumer and has the backing of Peter Thiel, Alan Howard, and Richard Li. 
Founded in 2021, Bullish manages approximately $10 billion in digital assets and cash. The company initially planned to go public through a special purpose acquisition company (SPAC) in 2021, but the plan was put on hold the following year.
Bullish Global did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
SEE ALSO: <a href="https://www.benzinga.com/25/02/43476651/if-you-invested-1000-in-bitcoin-when-robert-f-kennedy-jr-said-he-bought-2-btc-each-for-his-kids-heres-how-much-youd-have-now">If You Invested $1,000 In Bitcoin When Robert F. Kennedy Jr. Said He Bought 2 BTC Each For His Kids, Here&#8217;s How Much You&#8217;d Have Now</a>
Why It Matters: The IPO discussions coincide with a significant rise in the prices of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies since the U.S. election in November, with the total crypto market value escalating to over $3 trillion from nearly $2 trillion. Crypto enthusiasts are optimistic of better regulations under the Trump administration. One of the significant moves on this front is the SEC&#8217;s withdrawal of the SAB 121 accounting norm, which mandated banks and financial institutions to disclose cryptocurrencies as a liability on their balance sheet.
The U.S. House of Representatives and Senate are also establishing a joint task force to push forward cryptocurrency legislation. Venture Capitalist, David Sacks, appointed as the &#8216;<a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43477333/crypto-czar-sacks-says-potential-bitcoin-reserve-to-be-one-of-crypto-committees-first-priorities">crypto czar</a>&#8216; by President Donald Trump, unveiled a pro-crypto agenda on Tuesday, stating his goal of securing American leadership in digital assets.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43492011/exclusive-crypto-czar-charm-offensive-welcomed-but-experts-wonder-will-us-policy-deliver">&#8216;Crypto Czar&#8217; Charm Offensive Welcomed, But Experts Wonder: Will US Policy Deliver?</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Peter Thiel-Backed Crypto Exchange Reportedly Plans IPO In 2025 Amid Bitcoin And Digital Currency Boom

Press Releases

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

Management

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

Comments

Eterna Therapeutics

Eterna Therapeutics (ERNA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga